ALT → $5.50 by Jun 1, 2026.

Altimmune (ALT) just closed a big $225M oversubscribed funding round in late April, giving the company a solid runway to push its lead drug pemvidutide into Phase 3 for MASH. With Q1 earnings coming up on May 13, the stock looks primed for a bounce back toward the $5–6 zone as the financing overhang clears and investors focus on the upcoming catalysts. Smart money (RA Capital, Viking, Deep Track, etc.) piled in for a reason — they see real potential …